NF-κB is activated in patients with bortezomib-refractory primary MM and bortezomib-resistant MM, which is associated with the increased basal nuclear localization of NF-κB p65 (Raninga et al., 2016). Here, NFKB1 is linked to Miyoshi myopathy.